Nuclear Medicine Market Research Report Information by Type (Diagnosis [SPECT Radiopharmaceuticals {Tc99m, I-123, and Others} and PET Radiopharmaceuticals {F18, C11 Choline, and Others}] and Therapeutic (Alpha Emitters [Actinium-225 (Ac-225), Radium-223 (Ra-223), and Others], Beta Emitters [Yttrium-90 (Y-90), Lutetium-177 (Lu-177), and Others], and Brachytherapy Isotopes [Iodine-125 (I-125) and Others]), by Application (Neurology, Cardiology, Oncology [Prostate Cancer, Breast Cancer, Lung and Bronchus Cancer, Thyroid Cancer, Colorectal Canc

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA FLOW

3.2.1 DATA MINING PROCESS

3.3 PURCHASED DATABASE:

3.4 SECONDARY SOURCES:

3.4.1 SECONDARY RESEARCH DATA FLOW:

3.5 PRIMARY RESEARCH:

3.5.1 PRIMARY RESEARCH DATA FLOW:

3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED

3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE

3.6 APPROACHES FOR MARKET SIZE ESTIMATION:

3.6.1 REVENUE ANALYSIS APPROACH

3.7 DATA FORECASTING

3.7.1 DATA FORECASTING TYPE

3.8 DATA MODELING

3.8.1 MICROECONOMIC FACTOR ANALYSIS:

3.8.2 DATA MODELING:

3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 RISING PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES

4.2.2 TECHNOLOGICAL ADVANCEMENTS IN NUCLEAR MEDICINE

4.3 RESTRAINTS

4.3.1 SHORT HALF-LIFE OF RADIOPHARMACEUTICALS

4.3.2 SHORTAGE OF TRAINED MEDICAL PERSONNEL

4.4 OPPORTUNITY

4.4.1 USE OF RADIOPHARMACEUTICALS IN NEUROLOGICAL APPLICATIONS

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL

5.1.1 THREAT OF NEW ENTRANTS

5.1.2 BARGAINING POWER OF SUPPLIERS

5.1.3 THREAT OF SUBSTITUTES

5.1.4 BARGAINING POWER OF BUYERS

5.1.5 INTENSITY OF RIVALRY

5.2 IMPACT OF COVID-19 ON THE GLOBAL NUCLEAR MEDICINE MARKET

6 GLOBAL NUCLEAR MEDICINE MARKET, BY TYPE

6.1 OVERVIEW

6.2 DIAGNOSTIC

6.2.1 SPECT RADIOPHARMACEUTICALS

6.2.1.1 MO99/TC99M

6.2.1.2 I-123

6.2.1.3 OTHERS

6.2.2 PET RADIOPHARMACEUTICALS

6.2.2.1 F18

6.2.2.2 C11 CHOLINE

6.2.2.3 OTHERS

6.3 THERAPEUTIC

6.3.1 ALPHA EMITTERS

6.3.1.1 ACTINIUM-225 (AC-225)

6.3.1.2 RADIUM-223 (RA-223)

6.3.1.3 OTHERS

6.3.2 BETA EMITTERS

6.3.2.1 YTTRIUM-90 (Y-90)

6.3.2.2 LUTETIUM-177 (LU-177)

6.3.2.3 OTHERS

6.3.3 BRACHYTHERAPY ISOTOPE

6.3.3.1 IODINE-125 (I-125)

6.3.3.2 OTHERS

7 GLOBAL NUCLEAR MEDICINE MARKET, BY APPLICATION

7.1 OVERVIEW

7.2 NEUROLOGY

7.3 CARDIOLOGY

7.4 ONCOLOGY

7.4.1 PROSTATE CANCER

7.4.2 BREAST CANCER

7.4.3 LUNG AND BRONCHUS CANCER

7.4.4 THYROID CANCER

7.4.5 COLORECTAL CANCER

7.4.6 OTHERS

7.5 OTHERS

8 GLOBAL NUCLEAR MEDICINE MARKET, BY END USER

8.1 OVERVIEW

8.2 HOSPITALS AND DIAGNOSTIC CENTERS

8.3 RESEARCH INSTITUTES

8.4 OTHERS

9 GLOBAL NUCLEAR MEDICINE MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.2.3 MEXICO

9.3 EUROPE

9.3.1 GERMANY

9.3.2 FRANCE

9.3.3 UK

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA-PACIFIC

9.4.1 CHINA

9.4.2 INDIA

9.4.3 JAPAN

9.4.4 SOUTH KOREA

9.4.5 AUSTRALIA

9.4.6 REST OF ASIA-PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST & AFRICA

9.5.2 SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION

10.2 MARKET SHARE ANALYSIS, 2023

10.3 COMPETITOR DASHBOARD

10.4 PUBLIC PLAYERS STOCK SUMMARY

10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL

10.6.2 PARTNERSHIP

10.6.3 ACQUISITION

10.6.4 AGREEMENT

10.6.5 COLLABORATION

10.6.6 EXPANSION

11 COMPANY PROFILES

11.1 GE HEALTHCARE

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS/SERVICES OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 CARDINAL HEALTH

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 CURIUM

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 KEY STRATEGIES

11.4 NOVARTIS AG

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 SWOT ANALYSIS

11.4.6 KEY STRATEGIES

11.5 LANTHEUS

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 KEY STRATEGIES

11.6 JUBILANT RADIOPHARMA

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 KEY STRATEGIES

11.7 SIEMENS HEALTHINEERS

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.7.6 KEY STRATEGIES

11.8 BAYER AG

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

11.8.6 KEY STRATEGY

11.9 ECKERT & ZIEGLER

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 KEY STRATEGIES

11.10 BRACCO

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 KEY STRATEGY

12 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT

TABLE 2 GLOBAL NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2032 (USD MILLION)

TABLE 3 GLOBAL NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY REGION, 2021–2032 (USD MILLION)

TABLE 4 GLOBAL NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 5 GLOBAL NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY REGION, 2021–2032 (USD MILLION)

TABLE 6 GLOBAL NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 7 GLOBAL NUCLEAR MEDICINE MARKET, FOR MO99/TC99M, BY REGION, 2021–2032 (USD MILLION)

TABLE 8 GLOBAL NUCLEAR MEDICINE MARKET, FOR I-123, BY REGION, 2021–2032 (USD MILLION)

TABLE 9 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 10 GLOBAL NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY REGION, 2021–2032 (USD MILLION)

TABLE 11 GLOBAL NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 12 GLOBAL NUCLEAR MEDICINE MARKET, FOR F18, BY REGION, 2021–2032 (USD MILLION)

TABLE 13 GLOBAL NUCLEAR MEDICINE MARKET, FOR C11 CHOLINE, BY REGION, 2021–2032 (USD MILLION)

TABLE 14 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 15 GLOBAL NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY REGION, 2021–2032 (USD MILLION)

TABLE 16 GLOBAL NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 17 GLOBAL NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 18 GLOBAL NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 19 GLOBAL NUCLEAR MEDICINE MARKET, FOR ACTINIUM-225 (AC-225), BY REGION, 2021–2032 (USD MILLION)

TABLE 20 GLOBAL NUCLEAR MEDICINE MARKET, FOR RADIUM-223 (RA-223), BY REGION, 2021–2032 (USD MILLION)

TABLE 21 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 22 GLOBAL NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 23 GLOBAL NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 24 GLOBAL NUCLEAR MEDICINE MARKET, FOR YTTRIUM-90 (Y-90), BY REGION, 2021–2032 (USD MILLION)

TABLE 25 GLOBAL NUCLEAR MEDICINE MARKET, FOR LUTETIUM-177 (LU-177), BY REGION, 2021–2032 (USD MILLION)

TABLE 26 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 27 GLOBAL NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY REGION, 2021–2032 (USD MILLION)

TABLE 28 GLOBAL NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021–2032 (USD MILLION)

TABLE 29 GLOBAL NUCLEAR MEDICINE MARKET, FOR IODINE-125 (I-125), BY REGION, 2021–2032 (USD MILLION)

TABLE 30 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 31 GLOBAL NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2032 (USD MILLION)

TABLE 32 GLOBAL NUCLEAR MEDICINE MARKET, FOR NEUROLOGY, BY REGION, 2021–2032 (USD MILLION)

TABLE 33 GLOBAL NUCLEAR MEDICINE MARKET, FOR CARDIOLOGY, BY REGION, 2021–2032 (USD MILLION)

TABLE 34 GLOBAL NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY REGION, 2021–2032 (USD MILLION)

TABLE 35 GLOBAL NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 36 GLOBAL NUCLEAR MEDICINE MARKET, FOR PROSTATE CANCER, BY REGION, 2021–2032 (USD MILLION)

TABLE 37 GLOBAL NUCLEAR MEDICINE MARKET, FOR BREAST CANCER, BY REGION, 2021–2032 (USD MILLION)

TABLE 38 GLOBAL NUCLEAR MEDICINE MARKET, FOR LUNG AND BRONCHUS CANCER, BY REGION, 2021–2032 (USD MILLION)

TABLE 39 GLOBAL NUCLEAR MEDICINE MARKET, FOR THYROID CANCER, BY REGION, 2021–2032 (USD MILLION)

TABLE 40 GLOBAL NUCLEAR MEDICINE MARKET, FOR COLORECTAL CANCER, BY REGION, 2021–2032 (USD MILLION)

TABLE 41 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 42 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 43 GLOBAL NUCLEAR MEDICINE MARKET, BY END USER, 2021–2032 (USD MILLION)

TABLE 44 GLOBAL NUCLEAR MEDICINE MARKET, FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 45 GLOBAL NUCLEAR MEDICINE MARKET, FOR RESEARCH INSTITUTES, BY REGION, 2021–2032 (USD MILLION)

TABLE 46 GLOBAL NUCLEAR MEDICINE MARKET, FOR OTHERS, BY REGION, 2021–2032 (USD MILLION)

TABLE 47 GLOBAL NUCLEAR MEDICINE MARKET, BY REGION, 2021–2032 (USD MILLION)

TABLE 48 NORTH AMERICA NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021–2032 (USD MILLION)

TABLE 49 NORTH AMERICA NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2032 (USD MILLION)

TABLE 50 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 51 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 52 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 53 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 54 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 55 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 56 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021–2032 (USD MILLION)

TABLE 57 NORTH AMERICA NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2032 (USD MILLION)

TABLE 58 NORTH AMERICA NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 59 NORTH AMERICA NUCLEAR MEDICINE MARKET, BY END USER, 2021–2032 (USD MILLION)

TABLE 60 US NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2032 (USD MILLION)

TABLE 61 US NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 62 US NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 63 US NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 64 US NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 65 US NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 66 US NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 67 US NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021–2032 (USD MILLION)

TABLE 68 US NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2032 (USD MILLION)

TABLE 69 US NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 70 US NUCLEAR MEDICINE MARKET, BY END USER, 2021–2032 (USD MILLION)

TABLE 71 CANADA NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2032 (USD MILLION)

TABLE 72 CANADA NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 73 CANADA NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 74 CANADA NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 75 CANADA NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 76 CANADA NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 77 CANADA NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 78 CANADA NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021–2032 (USD MILLION)

TABLE 79 CANADA NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2032 (USD MILLION)

TABLE 80 CANADA NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 81 CANADA NUCLEAR MEDICINE MARKET, BY END USER, 2021–2032 (USD MILLION)

TABLE 82 MEXICO NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2032 (USD MILLION)

TABLE 83 MEXICO NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 84 MEXICO NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 85 MEXICO NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 86 MEXICO NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 87 MEXICO NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 88 MEXICO NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 89 MEXICO NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021–2032 (USD MILLION)

TABLE 90 MEXICO NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2032 (USD MILLION)

TABLE 91 MEXICO NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 92 MEXICO NUCLEAR MEDICINE MARKET, BY END USER, 2021–2032 (USD MILLION)

TABLE 93 EUROPE NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021–2032 (USD MILLION)

TABLE 94 EUROPE NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2032 (USD MILLION)

TABLE 95 EUROPE NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 96 EUROPE NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 97 EUROPE NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 98 EUROPE NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 99 EUROPE NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 100 EUROPE NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 101 EUROPE NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021–2032 (USD MILLION)

TABLE 102 EUROPE NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2032 (USD MILLION)

TABLE 103 EUROPE NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 104 EUROPE NUCLEAR MEDICINE MARKET, BY END USER, 2021–2032 (USD MILLION)

TABLE 105 GERMANY NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2032 (USD MILLION)

TABLE 106 GERMANY NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 107 GERMANY NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 108 GERMANY NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 109 GERMANY NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 110 GERMANY NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 111 GERMANY NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 112 GERMANY NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021–2032 (USD MILLION)

TABLE 113 GERMANY NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2032 (USD MILLION)

TABLE 114 GERMANY NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 115 GERMANY NUCLEAR MEDICINE MARKET, BY END USER, 2021–2032 (USD MILLION)

TABLE 116 FRANCE NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2032 (USD MILLION)

TABLE 117 FRANCE NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 118 FRANCE NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 119 FRANCE NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 120 FRANCE NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 121 FRANCE NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 122 FRANCE NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 123 FRANCE NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021–2032 (USD MILLION)

TABLE 124 FRANCE NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2032 (USD MILLION)

TABLE 125 FRANCE NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 126 FRANCE NUCLEAR MEDICINE MARKET, BY END USER, 2021–2032 (USD MILLION)

TABLE 127 UK NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2032 (USD MILLION)

TABLE 128 UK NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 129 UK NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 130 UK NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 131 UK NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 132 UK NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 133 UK NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 134 UK NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021–2032 (USD MILLION)

TABLE 135 UK NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2032 (USD MILLION)

TABLE 136 UK NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 137 UK NUCLEAR MEDICINE MARKET, BY END USER, 2021–2032 (USD MILLION)

TABLE 138 ITALY NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2032 (USD MILLION)

TABLE 139 ITALY NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 140 ITALY NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 141 ITALY NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 142 ITALY NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 143 ITALY NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 144 ITALY NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 145 ITALY NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021–2032 (USD MILLION)

TABLE 146 ITALY NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2032 (USD MILLION)

TABLE 147 ITALY NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 148 ITALY NUCLEAR MEDICINE MARKET, BY END USER, 2021–2032 (USD MILLION)

TABLE 149 SPAIN NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2032 (USD MILLION)

TABLE 150 SPAIN NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 151 SPAIN NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 152 SPAIN NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 153 SPAIN NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 154 SPAIN NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 155 SPAIN NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 156 SPAIN NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021–2032 (USD MILLION)

TABLE 157 SPAIN NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2032 (USD MILLION)

TABLE 158 SPAIN NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 159 SPAIN NUCLEAR MEDICINE MARKET, BY END USER, 2021–2032 (USD MILLION)

TABLE 160 REST OF EUROPE NUCLEAR MEDICINE MARKET, BY TYPE, 2021–2032 (USD MILLION)

TABLE 161 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR DIAGOSTIC, BY TYPE, 2021–2032 (USD MILLION)

TABLE 162 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 163 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 164 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR THERAPEUTICS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 165 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 166 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR BETA EMITTERS, BY TYPE, 2021–2032 (USD MILLION)

TABLE 167 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOPE, BY TYPE, 2021–2032 (USD MILLION)

TABLE 168 REST OF EUROPE NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021–2032 (USD MILLION)

TABLE 169 REST OF EUROPE NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2021–2032 (USD MILLION)

TABLE 170 REST OF EUROPE NUCLEAR MEDICINE MARKET, BY END USER, 2021–2032 (USD MILLION)

TABLE 171 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2019-2032 (USD MILLION)

TABLE 172 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)

TABLE 173 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 174 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 175 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 176 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 177 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 178 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 179 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)

TABLE 180 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)

TABLE 181 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)

TABLE 182 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)

TABLE 183 CHINA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)

TABLE 184 CHINA: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 185 CHINA: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 186 CHINA: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 187 CHINA: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 188 CHINA: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 189 CHINA: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 190 CHINA: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)

TABLE 191 CHINA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)

TABLE 192 CHINA: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)

TABLE 193 CHINA: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)

TABLE 194 INDIA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)

TABLE 195 INDIA: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 196 INDIA: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 197 INDIA: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 198 INDIA: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 199 INDIA: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 200 INDIA: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 201 INDIA: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)

TABLE 202 INDIA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)

TABLE 203 INDIA: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)

TABLE 204 INDIA: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)

TABLE 205 JAPAN: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)

TABLE 206 JAPAN: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 207 JAPAN: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 208 JAPAN: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 209 JAPAN: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 210 JAPAN: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 211 JAPAN: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 212 JAPAN: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)

TABLE 213 JAPAN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)

TABLE 214 JAPAN: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)

TABLE 215 JAPAN: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)

TABLE 216 SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)

TABLE 217 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 218 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 219 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 220 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 221 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 222 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 223 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)

TABLE 224 SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)

TABLE 225 SOUTH KOREA: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)

TABLE 226 SOUTH KOREA: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)

TABLE 227 AUSTRALIA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)

TABLE 228 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 229 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 230 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 231 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 232 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 233 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 234 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)

TABLE 235 AUSTRALIA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)

TABLE 236 AUSTRALIA: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)

TABLE 237 AUSTRALIA: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)

TABLE 238 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)

TABLE 239 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 240 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 241 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 242 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 243 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 244 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 245 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)

TABLE 246 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)

TABLE 247 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)

TABLE 248 REST OF ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)

TABLE 249 REST OT THE WORLD: NUCLEAR MEDICINE MARKET, BY REGION, 2019-2032 (USD MILLION)

TABLE 250 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)

TABLE 251 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 252 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 253 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 254 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 255 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 256 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 257 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)

TABLE 258 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)

TABLE 259 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)

TABLE 260 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)

TABLE 261 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)

TABLE 262 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 263 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 264 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 265 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 266 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 267 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 268 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)

TABLE 269 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)

TABLE 270 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)

TABLE 271 MIDDLE EAST & AFRICA: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)

TABLE 272 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2019-2032 (USD MILLION)

TABLE 273 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR DIAGNOSTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 274 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR SPECT RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 275 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR PET RADIOPHARMACEUTICAL, BY TYPE, 2019-2032 (USD MILLION)

TABLE 276 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR THERAPEUTIC, BY TYPE, 2019-2032 (USD MILLION)

TABLE 277 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR ALPHA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 278 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR BETA EMITTER, BY TYPE, 2019-2032 (USD MILLION)

TABLE 279 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR BRACHYTHERAPY ISOTOP, BY TYPE, 2019-2032 (USD MILLION)

TABLE 280 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2019-2032 (USD MILLION)

TABLE 281 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, FOR ONCOLOGY, BY TYPE, 2019-2032 (USD MILLION)

TABLE 282 SOUTH AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2019-2032 (USD MILLION)

TABLE 283 PUBLIC PLAYERS STOCK SUMMARY

TABLE 284 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

TABLE 285 PRODUCT LAUNCH/ PRODUCT APPROVAL

TABLE 286 PARTNERSHIP

TABLE 287 ACQUISITION

TABLE 288 AGREEMENT

TABLE 289 COLLABORATION

TABLE 290 EXPANSION

TABLE 291 GE HEALTHCARE: PRODUCTS OFFERED

TABLE 292 CARDINAL HEALTH: PRODUCTS OFFERED

TABLE 293 CARDINAL HEALTH: KEY DEVELOPMENTS

TABLE 294 CURIUM: PRODCUTS OFFERED

TABLE 295 CURIUM: KEY DEVELOPMENTS

TABLE 296 NOVARTIS AG: PRODUCT OFFERED

TABLE 297 LANTHEUS: PRODUCT OFFERED

TABLE 298 LANTHEUS: KEY DEVELOPMENTS

TABLE 299 JUBILANT RADIOPHARMA: PRODUCT OFFERED

TABLE 300 JUBILANT RADIOPHARMA: KEY DEVELOPMENTS

TABLE 301 SIEMENS HEALTHINEERS: PRODUCTS OFFERED

TABLE 302 BAYER AG: PRODUCTS OFFERED

TABLE 303 BAYER AG: KEY DEVELOPMENTS

TABLE 304 ECKERT & ZIEGLER: PRODUCT OFFERED

TABLE 305 ECKERT & ZIEGLER: KEY DEVELOPMENTS

TABLE 306 BRACCO: PRODUCT OFFERED

LIST OF FIGURES

FIGURE 1 GLOBAL NUCLEAR MEDICINE MARKET: STRUCTURE

FIGURE 2 GLOBAL NUCLEAR MEDICINE MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)

FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)

FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)

FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL NUCLEAR MEDICINE MARKET

FIGURE 6 GLOBAL NUCLEAR MEDICINE MARKET, BY TYPE, 2023 & 2032 (USD MILLION)

FIGURE 7 GLOBAL NUCLEAR MEDICINE MARKET SHARE (%), BY TYPE, 2023

FIGURE 8 GLOBAL NUCLEAR MEDICINE MARKET, BY APPLICATION, 2023 & 2032 (USD MILLION)

FIGURE 9 GLOBAL NUCLEAR MEDICINE MARKET SHARE (%), BY APPLICATION, 2023

FIGURE 10 GLOBAL NUCLEAR MEDICINE MARKET, BY END USER, 2023 & 2032 (USD MILLION)

FIGURE 11 GLOBAL NUCLEAR MEDICINE MARKET SHARE (%), BY END USER, 2023

FIGURE 12 GLOBAL NUCLEAR MEDICINE MARKET, BY REGION, 2023 & 2032 (USD MILLION)

FIGURE 13 GLOBAL NUCLEAR MEDICINE MARKET SHARE, BY REGION, 2023 (% SHARE)

FIGURE 14 NORTH AMERICA NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)

FIGURE 15 NORTH AMERICA NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023 (% SHARE)

FIGURE 16 EUROPE NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)

FIGURE 17 EUROPE NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023 (% SHARE)

FIGURE 18 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)

FIGURE 19 ASIA-PACIFIC: NUCLEAR MEDICINE MARKET SHARE (%), BY COUNTRY, 2023

FIGURE 20 REST OT THE WORLD: NUCLEAR MEDICINE MARKET, BY REGION, 2023 & 2032 (USD MILLION)

FIGURE 21 REST OT THE WORLD: NUCLEAR MEDICINE MARKET SHARE (%), BY REGION, 2023

FIGURE 22 NUCLEAR MEDICINE MARKET PLAYERS: COMPETITIVE ANALSIS, 2023

FIGURE 23 COMPETITOR DASHBOARD: GLOBAL NUCLEAR MEDICINE MARKET

FIGURE 24 GE HEALTHCARE: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 GE HEALTHCARE: SWOT ANALYSIS

FIGURE 26 CARDINAL HEALTH: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 CARDINAL HEALTH: SWOT ANALYSIS

FIGURE 28 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 NOVARTIS AG.: SWOT ANALYSIS

FIGURE 30 LANTHEUS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 SIEMENS HEALTHINEERS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 SIEMENS HEALTHINEERS: SWOT ANALYSIS

FIGURE 33 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 BAYER AG: SWOT ANALYSIS

FIGURE 35 ECKERT & ZIEGLER: FINANCIAL OVERVIEW SNAPSHOT